GGrantIndex
← Search

Core Support for Cancer Center

$250,747P30FY2021CANIH

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications, trials & patents

Paper 39499645Paper 39392861Paper 39378878Paper 39332920Paper 39259591Paper 39207105Paper 39193906Paper 39127153Paper 39081315Paper 39028768Paper 39025270Paper 38902475Paper 38898085Paper 38896451Paper 38863869Paper 38778498Paper 38753503Paper 38717519Paper 38700353Paper 38699331Paper 38679747Paper 38657656Paper 38645169Paper 38643166Paper 38608634Paper 38597673Paper 38571760Paper 38565851Paper 38559037Paper 38477945Paper 38463959Paper 38458178Paper 38436133Paper 38405931Paper 38402617Paper 38400039Paper 38387080Paper 38352476Paper 38334805Trial NCT05016622Trial NCT04514484Trial NCT04401670Trial NCT03648983Trial NCT02774291Trial NCT02649569Trial NCT02578888Trial NCT02575872Trial NCT02527304Trial NCT02507076Trial NCT02382419Trial NCT02277561Trial NCT02112552Trial NCT02073968Trial NCT02038153Trial NCT02009436Trial NCT01958580Trial NCT01939210Trial NCT01899326Trial NCT01899261Trial NCT01897454Trial NCT01897441Trial NCT01857271Trial NCT01772420Trial NCT01697293Trial NCT01695941Trial NCT01605032Trial NCT01408160Trial NCT01367301Trial NCT01351909Trial NCT01319539Trial NCT01231906Trial NCT01145430Trial NCT01142401Trial NCT01061606Trial NCT01041027Trial NCT01001910Trial NCT00950365Trial NCT00470301Trial NCT00450944Trial NCT00437034Trial NCT00392353Trial NCT00324740Trial NCT00182767Trial NCT00179348Trial NCT00121251Trial NCT00096317Trial NCT00066638Trial NCT00057863Trial NCT00055692Trial NCT00030706Trial NCT00019474Trial NCT00004864Trial NCT00004863Trial NCT00003867Trial NCT00002461Patent 9671391Patent 7709613Patent 6821725Patent 6013468Patent 5876979

Abstract

Cervical, anal, and oropharyngeal cancers are causally associated with high ?-HPV, particularly HPV16. The risks of these cancers are increased several-fold in persons living with HIV (PLWH) despite the widespread use of cART, and these risks increase further with diminishing CD4 count. Recently, a prospective nested case-control study by our research group (JAMA Oncol, 2016) found that not only HPV16 - but also certain ?-/?-HPV types - were strongly (independently) associated with incident head and neck squamous cell cancer (HNSCC). The odds ratios (ORs) ranged from OR=2.5 to OR=7.4 depending on the ?-/?-HPV type. Moreover, while HPV16 was only associated with tumors of the oropharynx, the ?-/?-HPV were prospectively associated with the incident development of tumors of the larynx, hypopharynx, oral cavity, as well as the oropharynx. In fact, ?-/?-HPV had a highly significant, independent association with oropharyngeal tumors even in those who tested positive for HPV16. ?-/?-HPV have known associations with skin cancer (SC) in patients with epidermodysplasia veruciformis, and are increasingly thought to play a role SC in general. SC incidence is highly elevated in PLWH and transplant patients (relative to the general population), consistent with an infectious cause. However, the role of ?-/?-HPV in cancer is thought to be distinct from that of HR ?-HPV. While HR ?-HPV are a necessary cause of cervical precancer/cancer, it is likely that ?-/?-HPV are more akin to a carcinogen. Whereas HR ?-HPV are found integrated or episomal in tumor cells, ?-/?-HPV are transient and cannot reliably be detected in tumors. Nonetheless, ?-/?-HPV are common, including in the oral cavity, cervicovaginal and anal specimens, and ?-/?-HPV prevalence increases with HIV and low CD4. To our knowledge, however, there have been no longitudinal studies to understand the natural history of cervical ?-/?-HPV in HIV[+] or HIV[-] women. More importantly, there have been no prospective studies of ?-/?-HPV and subsequent cervical pre-cancer/cancer. Prospective/longitudial studies are essential since, as mentioned, ?-/? HPV are transient and the virus may not be concurrent with cervical disease. We therefore propose studying ?-/?-HPV natural history and it?s relation with cervical precancer/cancer in the Women?s Interagency HIV Study (WIHS). Few if any other cohorts have the needed long-term follow-up with q6mo gynecological exams, Pap testing and colposcopy/biopsy (when indicated).

View original record on NIH RePORTER →